MetaCap

Imunon (IMNN) vs NuCana (NCNA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NuCana is the larger company by market cap ($3.6 million vs $3.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMNN-53.03%NCNA-34.25%
+13%-22%-56%
Oct 7, 20261 yearNov 20, 2026
IMNN-50.42%NCNA-31.86%
+18%-18%-54%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMNN versus NCNA key metrics
MetricIMNNNCNA
Share price$0.5355$0.7495
Market cap$3.47M$3.61M
1-day change-5.22%+4.39%
EPS (TTM)$-3.31$0.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-14.50M—
52-week high$4.35$4.55
52-week low$0.50$0.62
Distance from 52-week high-87.69%-83.53%
Analyst consensusstrong_buy—
Avg. price target upside+3074.60%—
Average volume150.49K118.13K
Shares outstanding6.49M4.82M
Employees2010
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Imunon

IMNN stock →

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

About NuCana

NCNA stock →

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

IMNN vs NCNA FAQ

Which is bigger, Imunon or NuCana?

NuCana (NCNA) is larger, with a market capitalization of $3.61M compared with $3.47M for Imunon (IMNN).

Are Imunon and NuCana in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons